Indications
Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
Composition
- Active substance
- nirogacestat hydrobromide
- International name (INN)
- nirogacestat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ogsiveo
- Active substance
- nirogacestat hydrobromide
- ATC code
- L01XX81
- Therapeutic area
- Desmoid Tumors
- Marketing authorisation holder
- Merck Europe B.V.
- Status